Oral Weight Loss Medication
Learn more about oral weight-loss medications available in the UK, including approved prescription treatments, their effectiveness and potential side effects. Find out how tablets compare with injectable medicines and why healthy lifestyle changes remain an important part of weight management.
Medically reviewed by Danny Gian Hou Chu, HCPC-Registered Physician Associate (PA38670).
Quick Guide: Prescription Medications for Weight Loss in the UK
| Jump to | What you’ll learn |
| What are oral weight loss medications? | Learn how prescription tablets work and who they’re designed for |
| Types of oral weight loss medication | Compare the different prescription tablets available in the UK |
| Who can take oral weight loss medication? | Find out your eligibility for oral prescription weight-loss treatment |
| Benefits of oral weight loss medication | Explore the advantages of prescription weight loss tablets |
| Side effects and safety | Learn about common side effects and important safety considerations |
| Choosing between tablets and injections | Factors to consider when deciding which type of prescription weight loss medication may be more suitable for you |
| How effective are oral weight loss tablets? | Discover what results clinical studies have shown |
| FAQs | Our team of registered medical professionals answer common questions about oral pill weight management in the UK |
What is Oral Weight Loss Medication?
Oral weight-loss medicines are prescription medications used to support weight management in people living with overweight or obesity by:
- Reducing appetite
- Increasing feelings of fullness
- Helping to control food intake
A newer generation of oral medicines works by mimicking naturally occurring hormones that regulate hunger and blood sugar levels. These are known as GLP-1 receptor agonists — a class of medicines that signal to the brain that you are full, helping to reduce appetite and calorie intake.
Unlike earlier GLP-1 treatments, which were only available as injections, newer oral formulations offer a tablet-based alternative for suitable patients.
Clinical studies suggest that newer oral GLP-1 medicines may help support meaningful weight loss when combined with healthy lifestyle changes.
Oral Weight Loss Medications Available in the UK
| Medication | Type | How It Works | Availability |
| Oral semaglutide (Wegovy pill) | GLP-1 medicine (appetite-regulating) | Helps regulate appetite and increase feelings of fullness | Prescription only |
| Orlistat | Lipase inhibitor | Reduces absorption of dietary fat | Prescription only |
| Mysimba (naltrexone/bupropion) | Appetite regulation medicine | Acts on appetite and reward pathways in the brain | Prescription only |
Eligibility for Oral Weight Loss Treatments
Your eligibility is based on two main factors: your body mass index (BMI) and any weight-related health conditions, in line with UK licensing criteria and guidance from the National Institute for Health and Care Excellence (NICE).
You may be eligible if you have:
A BMI of 30 or above (classed as obesity), or
A BMI of 27–30, plus at least one weight-related health problem, such as high blood pressure, type 2 diabetes or high cholesterol
For some medications, lower BMI thresholds apply if you’re from a South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background. These lower thresholds reflect evidence that certain ethnic groups face a higher risk of weight-related health conditions at a lower BMI.
Note: NHS eligibility criteria (set by NICE) are often stricter than the general licensing criteria above and typically require access through a specialist weight management service. Private eligibility criteria, like ours, are based on the medicine’s UK licence.
Think you may be eligible? Complete your free online consultation to find out whether prescription treatment may be appropriate for you.
Benefits of Oral Weight Loss Medication
Clinical studies suggest that oral GLP-1 medicines may offer benefits beyond weight loss,
supporting improvement in several obesity-related health measures.
Potential benefits include:
- Clinically meaningful weight reduction
- Reduced hunger and food cravings
- Increased feelings of fullness after meals
- Lower calorie intake
- Improved blood sugar control
- Improvements in blood pressure and cholesterol levels and other markers of metabolic health
- A convenient alternative to injections
While oral weight loss medicines can be effective, they work best when combined with healthy lifestyle changes and ongoing medical support.
Choosing Between Tablets & Injections
Both oral and injectable GLP-1 medicines can be options for weight management.
The best choice depends on your health needs, lifestyle, treatment goals, and personal preferences.
| Oral GLP-1 Tablets | Injectable GLP-1 Medicines |
| Taken by mouth once daily | Usually taken once weekly |
| No needles required | Less frequent dosing |
| May appeal to people who dislike injections | Longer track record in weight management |
| Convenient for many patients | Some injectable medicines have achieved higher average weight-loss results in clinical trials |
| Certain tablets may need to be taken on an empty stomach | Generally, fewer administrative requirements |
While injectable GLP-1 medicines currently have the strongest evidence for achieving the greatest weight loss, oral GLP-1 therapies may offer an effective alternative for patients who prefer a tablet-based treatment. Both options can support patients on their weight loss journey towards achieving and maintaining a healthy weight.
Side Effects & Safety
Like injectable GLP-1 medicines, oral GLP-1 weight-loss tablets are generally well tolerated in clinical studies, though side effects can occur.
In clinical trials such as ATTAIN-1 and OASIS-4, the most commonly reported side effects are gastrointestinal and include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Stomach discomfort
- Reduced appetite
These side effects are usually mild to moderate and often improve as treatment continues.
Rare but potentially serious side effects may include:
- Pancreatitis
- Gallbladder problems
- Severe dehydration
- Allergic reactions
Before starting treatment, it is important to discuss your medical history, current medications,
and any risk factors for complications with your healthcare professional.
Oral weight-loss medicines are most effective when used as part of a broader weight-management plan
that includes dietary guidance, lifestyle support, and long-term strategies to prevent weight gain.
How Effective Are Oral Weight Loss Tablets?
Results vary between individuals, and no medication works for everyone. Clinical trial findings represent average outcomes under controlled study conditions.
The effectiveness of oral weight-loss medications depends on the specific treatment, dose, adherence and accompanying lifestyle changes. Clinical trials have shown promising results for a new generation of oral GLP-1 weight loss medicines.
In the ATTAIN-1 trial, participants taking orforglipron achieved an average weight loss of up to 11.2% over 72 weeks, depending on the dose. Among those receiving the highest dose, more than half (54.6%) lost at least 10% of their starting body weight.
In the OASIS-4 trial, participants taking oral semaglutide achieved an average weight loss of 13.6% over 64 weeks, with 63% of participants losing at least 10% of their body weight.
In addition to weight loss, both studies reported improvements in blood sugar control, blood pressure, cholesterol levels, and other markers of metabolic health. These benefits may help reduce the risk of obesity-related conditions, including heart disease, type 2 diabetes and other serious illnesses.
FAQs
Frequently Asked Questions
Note: The following is for educational purposes only.
One of the newest prescription weight-loss treatments in the UK is the Wegovy weight-loss pill (oral semaglutide), approved by the MHRA in June 2026. It’s a weight-management medication taken daily alongside a balanced diet and physical activity.
Note: The following is for educational purposes only.
Yes, the MHRA-approved Wegovy weight-loss pills will be available on private prescription in mid-2026.
Read more: Everything you need to know about the Wegovy oral pill
Note: The following is for educational purposes only.
Possibly, but this should be planned with your prescriber as part of your treatment plan. The MHRA has confirmed a dosing pathway for moving from the weekly injection to the daily tablet, so you can maintain steady progress and manage the transition safely.
Yes. Clinical trial data show oral GLP-1 medicines can support meaningful weight loss by helping to regulate appetite and reduce hunger. For context, the injectable form of semaglutide produced an average weight loss of 14.9% over 68 weeks in its pivotal trial.
Oral semaglutide is among the most effective prescription weight-loss tablets currently available in the UK. In the OASIS-4 clinical trial, adults taking oral semaglutide lost an average of 13.6% of their body weight over 64 weeks when combined with lifestyle changes.
While average weight loss is generally greater with some weekly injectable GLP-1 medicines, oral semaglutide offers an effective tablet-based alternative for eligible patients. Individual results will vary.
Note: The following is for educational purposes only.
Not yet. Mounjaro (tirzepatide) is only available as an injection, and NICE guidance confirms this. Other oral weight management medications are in development, but they work differently and aren’t direct equivalents.
It depends on the tablet. Older treatments like orlistat tend to be cheaper, but newer oral GLP-1 medicines may cost a similar amount to injections, especially over the long term. Exact pricing should be confirmed directly with your provider.
Yes, if prescribed through a regulated UK provider following a clinical assessment. You’ll complete a consultation covering your medical history and any health problems, and a prescriber will check your eligibility before issuing a prescription.
Oral semaglutide (the Wegovy pill) is now available. Orlistat and Mysimba (naltrexone/bupropion) are also established tablet-based prescription weight-loss treatments, both of which are recommended by NICE for adults who meet specific BMI criteria.
Yes. Weight loss tablets work best as part of a wider plan that includes a balanced diet, healthy eating, and regular physical activity. NHS guidance recommends aiming for around 150 minutes of moderate activity a week alongside dietary change. These lifestyle changes also help you maintain your results over the long term.
Read more about oral weight-loss medication on our Envigore blog or join our support group on Facebook.
Disclaimer: The information on this page is intended for general educational purposes only. This should not be considered a substitute for personalised medical advice. If you have concerns about weight-related health conditions, please consult a healthcare professional.
At Envigore, we believe weight-related conversations should be respectful, supportive
and grounded in credible medical information. Our content is informed by clinical expertise and trusted research to help readers better understand the causes of weight gain and changes in body weight.
To maintain transparency and accuracy, we invite readers to explore the medical references and journals featured throughout this page.
National Institute for Health and Care Excellence (NICE). Technology Appraisal TA875 — Semaglutide for managing overweight and obesity. https://www.nice.org.uk/guidance/ta875/chapter/1-Recommendations
Medicines and Healthcare Products Regulatory Agency. (2026, June 11). First GLP-1 tablet for weight loss approved in the UK. GOV.UK. https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
Roberts, M. (2026, June 11). Weight-loss drug Wegovy to be available in pill form in UK for first time. https://www.bbc.com/news/articles/c9d2pl10lqzo
National Institute for Health and Care Excellence (NICE). Technology Appraisal TA1026 — Tirzepatide for managing overweight and obesity.
NHS England. Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/
NHS. Calories and weight loss — Better Health. https://www.nhs.uk/better-health/lose-weight/calorie-counting/
Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, Shaji C, Rubino D, Garvey WT; OASIS 4 Study Group. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025 Sep 18;393(11):1077-1087. doi: 10.1056/NEJMoa2500969. PMID: 40934115.
Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056/NEJMoa2511774. Epub 2025 Sep 16. PMID: 40960239.
Santulli, G. From needles to pills: oral GLP-1 therapy enters the obesity arena. Cardiovasc. Diabetol. – Endocrinol. Rep. 11, 31 (2025). https://doi.org/10.1186/s40842-025-00245-5
Klobučar, S., Belančić, A., Bukša, I., Morić, N., & Rahelić, D. (2024). Effectiveness of Oral versus Injectable Semaglutide in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia. Diabetology, 5(1), 60-68. https://doi.org/10.3390/diabetology5010005
About Your Clinical Team
This content was medically reviewed and approved by Danny Gian Hou Chu, an HCPC-registered Physician Associate (PA38670), who oversees all prescribing decisions at Envigore.
All prescriptions are dispensed by Right Medicine Pharmacy, a GPhC-Registered Pharmacy (No. 9012382).
Nutritional guidance and lifestyle support are provided by Veronica Giudice, an HCPC-registered dietitian (DT26570) and British Dietetic Association member.
Last medically reviewed: July 2026